Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL18045885

CC(C)N(C(=O)c1cccc(C(F)(F)F)c1)c1ccccc1/C=C/C(=O)NO.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.44
▸ HDAC1 Q13547 7/20 0.44
▸ HDAC8 Q9BY41 6/20 0.44
▸ OPRM1 P35372 1/20 0.41
▸ OPRL1 P41146 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ HDAC3 O15379 4/20 0.40
▸ HDAC2 Q92769 4/20 0.40
▸ HDAC10 Q969S8 4/20 0.40
▸ HDAC11 Q96DB2 4/20 0.40
▸ HDAC6 Q9UBN7 4/20 0.40
▸ HDAC5 Q9UQL6 4/20 0.40
▸ HDAC4 P56524 3/20 0.40
▸ HDAC7 Q8WUI4 3/20 0.40
▸ HDAC9 Q9UKV0 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ ADAM17 P78536 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ GPR139 Q6DWJ6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL18045888 1.00 MAOB (0.44) MAOBHDAC1HDAC8OPRM1OPRL1
SCHEMBL18046750 0.96 HDAC1 (0.47) MAOBHDAC1HDAC8OPRM1OPRL1
SCHEMBL18046753 0.96 HDAC1 (0.47) MAOBHDAC1HDAC8OPRM1OPRL1
SCHEMBL18046316 0.84 MAOB (0.47) MAOBHDAC8OPRM1OPRL1NPSR1
SCHEMBL18046319 0.84 MAOB (0.47) MAOBHDAC8OPRM1OPRL1NPSR1
SCHEMBL18046109 0.84 GPBAR1 (0.50) MAOBHDAC1HDAC8OPRM1OPRL1
SCHEMBL18046108 0.84 GPBAR1 (0.50) MAOBHDAC1HDAC8OPRM1OPRL1
SCHEMBL29608465 0.84 GPBAR1 (0.50) MAOBHDAC1HDAC8OPRM1OPRL1
SCHEMBL18046069 0.77 HDAC8 (0.43) HDAC1HDAC8OPRM1HDAC3HDAC2
SCHEMBL18046072 0.77 HDAC8 (0.43) HDAC1HDAC8OPRM1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO HEALTH, INC. (US) 2024-03-05 — — US disclosed
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2022-03-10 — — US disclosed
EP-3932914-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, Inc. (US) 2022-01-05 — — EP disclosed
US-10988441-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-27 — — US disclosed
US-20200331847-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2020-10-22 — — US disclosed
US-10508077-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-12-17 — — US disclosed
US-20190241506-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2019-08-08 — — US disclosed
US-10266487-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
US-20180297939-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2018-10-18 — — US disclosed
US-20180044282-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO EARLY DISCOVERY, INC. 2018-02-15 — — US disclosed
EP-3268358-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Forma Therapeutics, Inc. (US) 2018-01-17 — — EP disclosed
US-9745253-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2017-08-29 — — US disclosed
WO-2016149099-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-09-22 — — WO disclosed
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044282-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-20200331847-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-10988441-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-10508077-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-10266487-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-20190241506-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885
US-20180297939-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 MAOB 3294/4885HDAC1 3/4885HDAC8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback